Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.42 |
| ▸ | GOT1 | P17174 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.33 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31092383 | 0.78 | GRIN1 (0.40) | GOT1CYP1A2RXRAGRIN1GRIN2B | |
| SCHEMBL16235549 | 0.78 | GRIN1 (0.40) | GOT1CYP1A2RXRAGRIN1GRIN2B | |
| SCHEMBL907708 | 0.77 | CYP1A2 (0.45) | KMT2ASMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12878804 | 0.77 | CTDSP1 (0.36) | KMT2AMEN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL29385144 | 0.77 | — | — | |
| SCHEMBL910326 | 0.77 | — | — | |
| SCHEMBL129824 | 0.76 | CTDSP1 (0.32) | CYP1A2CTDSP1 | |
| SCHEMBL4273120 | 0.76 | ALDH1A1 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Ammonia Solution, Strong SCHEMBL28259089 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL4479594 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685729-B2 | C5a receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-06-27 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2011117254-A1 | PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR | PROSIDION LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| US-7605215-B2 | Process for producing olefin copolymerization catalyst and process for producing olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-20 | — | — | US | disclosed |
| CN-101333187-A | Novel PI3K enzyme inhibitors and uses thereof | UNIV EAST CHINA SCIENCE & TECH (CN) | 2008-12-31 | — | — | CN | disclosed |
| US-20080227937-A1 | Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | GABRA1 3700/4885GABRG2 3430/4885GABRB3 2798/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | GABRA1 3402/4885GABRG2 3125/4885GABRB3 2360/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | GABRA1 3149/4885GABRG2 2769/4885GABRB3 2454/4885 |
| US-11685729-B2 | C5a receptor modulators | C5AR1, C3AR1, C5AR2 | GABRA1 586/4885GABRG2 999/4885GABRB3 1547/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | GABRA1 3402/4885GABRG2 3125/4885GABRB3 2360/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | GABRA1 2885/4885GABRG2 2484/4885GABRB3 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.